Louisiana State Employees Retirement System Cuts Stock Holdings in Haemonetics Co. (NYSE:HAE)

Louisiana State Employees Retirement System trimmed its position in shares of Haemonetics Co. (NYSE:HAE) by 2.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,900 shares of the medical instruments supplier’s stock after selling 300 shares during the period. Louisiana State Employees Retirement System’s holdings in Haemonetics were worth $1,085,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Nisa Investment Advisors LLC raised its stake in shares of Haemonetics by 124.2% during the third quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock valued at $92,000 after acquiring an additional 632 shares during the last quarter. KBC Group NV raised its stake in shares of Haemonetics by 54.6% during the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier’s stock valued at $157,000 after acquiring an additional 712 shares during the last quarter. iSAM Funds UK Ltd bought a new position in shares of Haemonetics during the third quarter valued at about $204,000. CWC Advisors LLC. bought a new position in shares of Haemonetics during the third quarter valued at about $231,000. Finally, Versor Investments LP raised its stake in Haemonetics by 9.1% in the third quarter. Versor Investments LP now owns 3,600 shares of the medical instruments supplier’s stock worth $289,000 after buying an additional 300 shares in the last quarter. 99.67% of the stock is owned by institutional investors.

Haemonetics Price Performance

Shares of HAE opened at $62.47 on Tuesday. The firm’s 50-day simple moving average is $74.18 and its two-hundred day simple moving average is $77.22. Haemonetics Co. has a fifty-two week low of $58.80 and a fifty-two week high of $97.97. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.09 and a current ratio of 3.97. The stock has a market cap of $3.14 billion, a PE ratio of 24.59, a price-to-earnings-growth ratio of 0.98 and a beta of 0.39.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Analysts anticipate that Haemonetics Co. will post 4.59 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on HAE. Raymond James reissued a “strong-buy” rating and issued a $115.00 price target (down from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. JMP Securities decreased their price target on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research note on Friday, February 7th. JPMorgan Chase & Co. began coverage on shares of Haemonetics in a research note on Friday, December 6th. They issued an “overweight” rating and a $116.00 price target for the company. StockNews.com downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Bank of America downgraded shares of Haemonetics from a “neutral” rating to an “underperform” rating and decreased their price target for the stock from $95.00 to $68.00 in a research note on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $101.67.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.